Safe solutions for your central-venous catheter
Central-venous catheters (CVC) help patients in various medical contexts – whether it be dialysis, cancer treatment, or parenteral nutrition. But while vascular access devices (short VAD) can save lives, they also come with considerable risks.
To prevent catheter-associated infections, we have developed TauroLock™. This lock solution yields several effects with just one product:
For that purpose, we use several substances: taurolidine, heparin, citrate, and urokinase. TauroLock™ solutions can thus be assigned according to the patient’s individual needs.
Why Do You Need the Right Catheter Lock Solution?
If a CVC system does not remain completely sanitary at all times, it may lead to dangerous infections. Furthermore, it is important to avoid the formation of biofilm within CVCs, which creates a three-dimensional matrix for germs. How do we ensure that central-venous catheters do not cause further complications, or even life-threatening complications? Our answer is: TauroLock™. Unlike traditional lock solutions, we use a combination of active components to realise multiple effects at once.
Taurolidine is antimicrobial:
It kills more than 500 germs without generating resistance. This includes MRSA (methicillin-resistentant staphylococcus aureus) and VRE (vancomycin-resistant enterococci).
Heparin and citrate
They prevent occlusion and sustain a patient’s flow rate.
Urokinase is fibrinolytic:
It serves to break up blood clotting in its early stages.
Used in the right concentration, these substances provide the basis for a lock solution that prevents catheter-related bloodstream infections (CRBSI) and occlusions.
When Do You Need TauroLock™ Solutions?
Our products are suitable for a wide range of patients. Generally speaking, we recommend using TauroLock™ solutions in all central access devices (CAD) such as those used in:
Patients who depend on extracorporeal blood cleansing due to permanent kidney failure may use TauroLock™-Hep500, TauroLock™-U25.000, or TauroLock™.
Patients who undergo treatments such as chemotherapy to fight cancer may use TauroLock™, TauroLock™-HEP100, or TauroLock™-U25.000.
Intensive Care Units
Patients in ICU should use TauroLock™ or TauroLock™-HEP100 according to their medical condition.
In order to meet the challenges that each patient faces, we have created a customised product line. You may thus choose from various lock solutions containing taurolidine and citrate, as well as heparin (in different dosages) or urokinase.
|Product||Ingredients||Recommended Fields of Application|
Each catheter lock solution from our TauroLock™ series functions both efficiently and safely. Throughout testings, taurolidine has proven to be of good biocompatibility and clinical tolerability: Once the substance enters the body through the VAD, it degrades to taurine (amino acid), carbon dioxide, and water.
Want to Learn More about Our Lock Solutions?
On this website, you can find concise information about the usage and benefits of TauroLock™. If you have any specific questions or concerns, we are happy to help any time. Feel free to contact us via:
“In vitro, the antimicrobial agent taurolidine inhibited virtually all of the bacteria tested, including vancomycin-resistant enterococci, oxacillin-resistant staphylococci, and Stenotrophomonas maltophilia, at concentrations between 250 and 2,000 mg/ml. Taurolidine was not effective in experimental endocarditis. While it appears unlikely that this antimicrobial would be useful for systemic therapy, its bactericidal activity and the resistance rates found (<10-9) are favorable indicators for its possible development for topical use.”